Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 29 2025
0mins
Source: Globenewswire
Clinical Trial Announcement: Alzamend Neuro has initiated its first Phase II clinical study of AL001, a novel lithium-delivery system aimed at treating Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, with the first patient dosed in collaboration with Massachusetts General Hospital.
Potential Impact of AL001: The new formulation of AL001 is designed to enhance brain absorption of lithium while reducing systemic side effects, potentially eliminating the need for therapeutic drug monitoring and improving treatment outcomes for over 43 million Americans suffering from these conditions.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
